Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Psoralen Photochemotherapy (PUVA) and Pregnancy

Psoralen Photochemotherapy (PUVA) and Pregnancy Abstract † Background and Design.— Psoralen photochemotherapy (PUVA) may carry a risk of mutagenesis and teratogenesis. Using a medical birth registry and other health registries, infants born to women who had been treated with PUVA were identified. Exposure information was obtained from treating hospitals and from the license-granting agency. A total of 504 infants were born of pregnancies occurring after PUVA treatment, and 689 infants were born of pregnancies occurring before such treatment. In another 14 cases, treatment occurred during pregnancy. Results.— No increase in infant or child mortality or in the presence of congenital malformations could be seen after PUVA treatment. There was a marked increase in low-birth-weight infants when pregnancy occurred after treatment, and this is probably not explained by maternal smoking, but could be an effect of the underlying disease. Conclusions.— The theoretical mutagenic and teratogenic effect of PUVA treatment apparently does not carry any significant risk for abnormal delivery outcome.(Arch Dermatol. 1993;129:320-323) References 1. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study . Lancet . 1991;338:91-93.Crossref 2. Higgins EM, Todd P, du Vivier AWP. PUVA and cancer . Lancet . 1991;338:703-704.Crossref 3. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis . Arch Dermatol . 1991;127: 347-350.Crossref 4. Cnattingius S, Ericson A, Gunnarskog G, Källén B. A quality study of a medical birth registry . Scand J Soc Med . 1990;18:143-148. 5. Källén B. Search for teratogenic risks with the aid of malformation registries . Teratology . 1987;35:47-52.Crossref 6. Ericson A, Gunnarskog G, Källén B, Otterblad-Olausson P. Surveillance of smoking during pregnancy in Sweden, 1983-1987 . Acta Obstet Gynecol Scand . 1991;70:111-117.Crossref 7. Lindelöf B, Sigurgeirsson B. PUVA treatment in Sweden . Acta Derm Venereol . 1992;169( (suppl) ):1-6. 8. Risch N, Reich EW, Wishnick M, McCarthy JG. Spontaneous mutation and parental age in humans . Am J Hum Genet . 1987;41: 218-248. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Loading next page...
 
/lp/american-medical-association/psoralen-photochemotherapy-puva-and-pregnancy-BNtusCeQD4
Publisher
American Medical Association
Copyright
Copyright © 1993 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1993.01680240060006
Publisher site
See Article on Publisher Site

Abstract

Abstract † Background and Design.— Psoralen photochemotherapy (PUVA) may carry a risk of mutagenesis and teratogenesis. Using a medical birth registry and other health registries, infants born to women who had been treated with PUVA were identified. Exposure information was obtained from treating hospitals and from the license-granting agency. A total of 504 infants were born of pregnancies occurring after PUVA treatment, and 689 infants were born of pregnancies occurring before such treatment. In another 14 cases, treatment occurred during pregnancy. Results.— No increase in infant or child mortality or in the presence of congenital malformations could be seen after PUVA treatment. There was a marked increase in low-birth-weight infants when pregnancy occurred after treatment, and this is probably not explained by maternal smoking, but could be an effect of the underlying disease. Conclusions.— The theoretical mutagenic and teratogenic effect of PUVA treatment apparently does not carry any significant risk for abnormal delivery outcome.(Arch Dermatol. 1993;129:320-323) References 1. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study . Lancet . 1991;338:91-93.Crossref 2. Higgins EM, Todd P, du Vivier AWP. PUVA and cancer . Lancet . 1991;338:703-704.Crossref 3. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis . Arch Dermatol . 1991;127: 347-350.Crossref 4. Cnattingius S, Ericson A, Gunnarskog G, Källén B. A quality study of a medical birth registry . Scand J Soc Med . 1990;18:143-148. 5. Källén B. Search for teratogenic risks with the aid of malformation registries . Teratology . 1987;35:47-52.Crossref 6. Ericson A, Gunnarskog G, Källén B, Otterblad-Olausson P. Surveillance of smoking during pregnancy in Sweden, 1983-1987 . Acta Obstet Gynecol Scand . 1991;70:111-117.Crossref 7. Lindelöf B, Sigurgeirsson B. PUVA treatment in Sweden . Acta Derm Venereol . 1992;169( (suppl) ):1-6. 8. Risch N, Reich EW, Wishnick M, McCarthy JG. Spontaneous mutation and parental age in humans . Am J Hum Genet . 1987;41: 218-248.

Journal

Archives of DermatologyAmerican Medical Association

Published: Mar 1, 1993

References